amgen face biosimilar newer drug grow
updat forecast estim jun
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jun
estim jun
price data jun
rate updat jun
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
root provid supportive-car product kidney
diseas cancer patient free cash flow hover sale
firm benefit massiv cost-cut improv
manufactur strong newer blockbust like prolia/xgeva
futur blockbust cholesterol drug repatha defend
wide moat eros due biosimilar brand
biolog vulner biosimilar
age eas manufactur innov brand drug
also steal share tougher label reimburs
affect anemia drug epogen aranesp sinc safeti concern
emerg launch biosimilar retacrit
weigh sale neutropenia drug
biosimilar competit year key longer-act
drug neulasta began see declin key market
due two biosimilar launch effect brand
competitor pois continu erod enbrel share
enbrel patent run think biosimilar humira
expect could pull sale tnf class
address headwind invest heavili
more-effici manufactur undertaken massiv
cost-cut program defend margin reinvest research
develop promot new area like cardiolog
larg biosimilar pipelin begin
launch europ low manufactur cost could make
viabl biosimilar player well
newer drug pipelin also key counter
biosimilar version older drug prolia osteoporosi xgeva
fractur prevent cancer patient see
billion peak sale kyproli -- acquir onyx
pois becom billion product multipl myeloma
repatha cholesterol-low look like biggest opportun
estim billion peak sale also bullish
posit aimovig launch migrain
myeloma phase lung cancer
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer support care product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rais fair valu estim per share
slightli increas estim phase
oncolog drug follow data announc
think firm capabl averag top-lin sale
growth bottom-lin growth
enbrel profit share end signific
cost-cut non-gaap oper margin improv
peak nearli expect
futur margin remain near even addit
invest sell gener administr
expens due stronger manufactur effici
confid potenti biosimilar pipelin
compet global includ billion biosimilar
sale
price power erod think enbrel sale
continu declin brand aranesp competit
mircera well epogen biosimilar launch
weigh anemia drug sale expect neulasta sale
begin fall significantli biosimilar launch
 market assum averag annual declin
neutropenia
neulasta
next year
expect combin prolia/xgeva sale peak billion
forecast peak cholesterol-low sale billion
includ repatha sale well assum royalti
 praluent sale begin peak sale
migrain drug aimovig around billion peak global
sale osteoporosi drug even billion
also see newer cancer drug like blincyto imlyg
smaller opportun billion peak despit
posit data endeavor studi
multipl myeloma market gotten
competit think sale onyx kyproli could
peak billion
assum cost capit rate systemat
risk surround share averag
cost equiti assumpt align capit cost
assumpt return equiti investor like
demand long run access
previous off-shore cash expect emphas
dividend share repurchas model slightli
declin gross debt near term note debt
level could easili increas undertak
large-scal acquisit assum pre-tax cost
debt reflect normal
confid capabl defend
bottom-lin key period weak legaci
product cost-cut manufactur innov help
trim oper cost howev abil grow
heavili depend repatha abil move past payer
restrict well futur potenti restrict
aimovig migrain even osteoporosi
therefor assign diversifi biotech medium
repatha sale assumpt well futur oper
margin key assumpt behind fair valu
estim base-cas scenario assum adjust
oper margin declin remain near
royalti sale praluent revenu
repatha praluent reach billion
bull-cas scenario assum adjust oper
margin remain assum obtain
royalti sale praluent
revenu hit billion result fair
valu estim per share
bear-cas scenario assum adjust oper
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
epogen aranesp sinc well biosimilar
competit anemia neutropenia drug
establish europ nascent gener
biosimilar pressur sever biolog
larg
manufactur difficulti cost clinic trial
product market creat high barrier entri
limit number entrant addit amgen
longer-act product aranesp neulasta help
defend biosimilar threat older product
margin declin low repatha sale
billion praluent royalti persist
difficulti payer reimburs result fair
valu estim per share
market sever blockbust biolog therapi
oncolog immunolog market give
intang asset form foundat wide moat
one origin biotech launch innov
anemia neutropenia
begin epogen
longer-act product aranesp neulasta
launch firm decid acquir
immunex bring enbrel portfolio highli
profit biolog continu drive strong free cash
flow firm gener around sale expect
see steadi free cash flow margin level
return invest capit remain cost
capit forese futur
continu grow despit steadi regulatori
also highli diversifi enbrel account
sale repatha pois top
product sale strong growth enbrel
neutropenia drug counter epogen aranesp
headwind past year prolia/xgeva
approv osteoporosi cancer indic
reach blockbust statu renal diseas
drug sensipar onyx acquisit multipl
myeloma drug kyproli gener strong data
expand sale support european launch
competit like prevent signific uptak
see moat trend stabl think newli
launch product higher rate product
late-stag pipelin -- brand biosimilar -- allow
firm sustain strong roic new lower-cost
manufactur technolog aggress cost-cut
effort price volum pressur biosimilar
competit weigh heavili long-term margin
reimburs new competit brand
biosimilar biggest headwind moat
trend reimburs dialysi drug epogen bundl
dialysi product although contract
competit price margin pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
also bullish abil compet
biosimilar market given firm effici manufactur
practic establish oncolog immunolog salesforc
regulatori legal expertis advanc pipelin
assum partner allergan hold
share global biosimilar market
believ manufactur improv could boost
biosimilar emerging-market opportun
product also among oldest --
profit -- market biolog mani among
first see biosimilar competit key patent
epogen neulasta expir
three product account top
line biosimilar competit europ mild
impact epogen sale focus
 brand neulasta shield
biosimilar competit neulasta sale
 howev epogen biosimilar
biosimilar neulasta coheru
launch earli overal expect
averag annual sale declin epogen
neutropenia franchis addit arthriti
psoriasi drug enbrel see high level new
competit assum double-digit sale declin
begin ahead humira biosimilar launch
top
howev regard pipelin product think amgen
turn corner think firm abl
line despit pressur current
blockbust histor high failur rate
pipelin particularli oncolog pipelin
decis return brodalumab
right astra due higher rate suicid also hit
late-stag pipelin howev cholesterol drug
repatha launch europ
despit slow start expect antibodi class
could gener billion peak sale
sanofi/regeneron praluent remain well ahead key
candid even met key superior endpoint forteo
phase trial cardiovascular side
drug
bone-form mechan action could complement
prolia migrain drug aimovig launch
could see billion peak potenti
limit broad uptak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin product sinc
launch prolia/xgeva cholesterol drug repatha
migrain drug aimovig reviv
enthusiasm firm research engin
obiosimilar market europ sinc
biosimilar could larger impact
version epogen neulasta hit
acquisit decod give firm
abil identifi potenti new drug target valid
human genet
improv manufactur effici
benefit gross margin also could give firm
cost advantag nascent biosimilar market
alreadi launch two product europ
oth payoff billion acquisit
onyx highli depend success kyproli
johnson johnson/genmab darzalex
bcma-target therapi like strong
lack focu biotech peer
drug target larg market like osteoporosi
cardiolog specialti market like immunolog
oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end held billion cash
billion debt expect gener roughli
billion free cash flow annual next year
combin one-tim repatri off-shore cash
end suffici handl
debt come due well firm share-repurchas
program billion repurchas dividend
program dividend increas rise
biosimilar uptak remain biggest risk
neulasta epogen biosimilar
launch regulatori reimburs chang
could continu plagu aranesp epogen includ
medicar dialysi reimburs cut enbrel key
growth driver grow competit
rheumatoid arthriti psoriasi could weigh
firm market share price power evapor
overal price power could wane propos
medicar part reimburs
implement given firm relianc medicar
high proport sale addit sever
newer product enter highli competit market
prolia compet establish drug novarti
reclast cheaper gener bisphosphon vectibix
compet roch avastin eli lilli
kyproli lead proteasom inhibitor velcad
posit comparison fail differenti
kyproli first-lin set billion
acquisit onyx could prove expens repatha
shown signific abil reduc advers cardiovascular
event benefit may enough loosen payer
restrict limit patient access drug aimovig
also enter crowd market similar drug
entrant eager discount price gain share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mr robert bradwayceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund invmt co amer
america corpor
new york mellon corp
fidel manag research compani
capit research manag compani
share
fund
share
fund
assign amgen standard mark stewardship
firm engin struggl churn
promis drug candid sinc launch prolia/xgeva
believ new blood might benefici firm
product futur share perform sale
profit skyrocket reign ceo
chairman kevin sharer signific multipl
compress led flat perform firm share
tenur former presid bob bradway
replac sharer ceo may board chairman
start bradway advanc
sinc arriv vice presid oper
wish firm select someon longer
record pharmaceut industri
bradway year think
experi would particularli use
firm face steep biosimilar competit need
cohes strategi hope keep top-lin growth
posit territori said cfo david melin
appear make necessari cost cut achiev
left posit head research develop
posit sinc replac roger
perlmutt februari execut vice presid
global commerci oper anthoni hooper also
retir howev encourag progress
new leadership new head david rees
medic background serv sinc
new oper head murdo gordon join
bristol-my squibb formerli chief commerci offic
made sever shareholder-friendli move
recent histori share repurchas tender offer level
fair valu estim appear good use
cash quarterli dividend grew roughli annual
initi level continu grow
double-digit rate howev remain wari firm
compens polici reward execut easili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manipul ep growth instead return invest
capit board structur enough healthcare-rel
experi member former ceo
robert eckert phillip ceo greg garland
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
share fairli valu oncolog catalyst approach
maintain fair valu estim amgen
disappoint view larg neulasta sale
enbrel adjust partli mask underli
weak key older franchis mediocr sale
migrain drug aimovig first quarter also appear
affect price discount discontinu well
competit
migrain market
maintain below-consensu estim drug
growth impress aggress price cut
last fall annual expect growth franchis
increas addit rapidli advanc
oncolog portfolio data bcma bispecif
kras-target small molecul expect
june includ placehold
potenti sale bcma kra program
model overal think newer product
counter hit biosimilar competit allow
firm maintain stabl wide moat
updat estim impli perform near
midpoint new rang
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
maintain fve control pipelin
maintain fair valu estim amgen
follow in-lin result disappoint guidanc
slightli reduc sale forecast
legaci product reflect steep
competit price pressur larg maintain
forecast newer brand portfolio
increas biosimilar portfolio
assumpt howev cost control key
valuat despit heavi biosimilar pressur neulasta
epogen oper expens pois stay
rel flat minim oper margin pressur
allow see posit ep growth
help share repurchas
saw flat first-quart revenu billion
osteoporosi drug prolia repatha cancer drug kyproli
yield double-digit growth counter biosimilar
pressur neulasta anemia drug
aranesp epogen respect
well at-risk gener pressur sensipar
non-gaap earn per share grew larg due share
repurchas oper margin fell basi point
gross margin hit appear result
price reduct due biosimilar competit amgen
slow invest oncolog research
develop expens growth quarter despit flat
sale manag narrow top- bottom-lin
guidanc year favor higher end guidanc
share recent trade slight discount
valuat think wide moat remain
support core product prolia/xgeva newer launch
repatha cholesterol lower aimovig migrain
earli pipelin multipl oncolog program asthma
drug tezepelumab enbrel sensipar patent litig
remain risk valuat although alreadi
substanti declin sensipar built model
patent settlement
acceler double-digit declin remaind
forecast enbrel due brand competit
upsid aimovig estim remain consensu
launch acceler exceed estim
could increas valuat addit sever early-stag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oncolog trial read includ once-weekli
bcma-target biolog could boost long-
neulasta face two biosimilar competitor unit
state far -- fulphila coheru
udenyca -- potenti third end year list
price fulphila udenyca third lower
neulasta neulasta discount on-bodi
deliveri system market make biosimilar
slightli less compel increas neulasta
declin base initi traction
fulphila cautiou commentari overal
price commentari estim mid-single-digit
price pressur portfolio epogen
face retacrit biosimilar offer
similar discount neulasta biosimilar epogen
contract offer mitig
potenti volum declin epogen
sale also includ stage price declin
detail patent exposur pipelin
pleas see recent healthcar observ annual drug
pipelin report moat remain secur innov
counter price gener headwind
acceler report also discuss view large-
scale industri cash balanc
billion strong free cash flow gener give
mean take action lacklust intern growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
